BDTX$2.67
$2.71
Chart
Performance
Key Stats
AI BDTX Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralBlack Diamond Therapeutics (BDTX) exhibits promising advancements in its clinical pipeline (thematic strength), but faces significant financial challenges and negative profitability trends (fundamental weakness). Technical indicators are mixed, suggesting a period of consolidation rather than strong upward momentum.
Thematic
BDTX is focused on precision oncology targeting specific genetic mutations, a high-growth and innovative area within the pharmaceutical sector. The company's lead candidates address significant unmet medical needs in difficult-to-treat cancers.
Fundamental
BDTX is a clinical-stage company with no current revenue and significant operating losses. The company relies on cash reserves and potential future financing, making it a high-risk investment from a financial health perspective.
Technical
BDTX is trading below its 52-week high, indicating recent downward pressure. While some short-term indicators suggest potential buying opportunities, the overall trend remains subdued, with resistance levels posing challenges.
| Factor | Score |
|---|---|
| Oncology Focus (Precision Medicine) | 90 |
| Clinical Pipeline Progression | 80 |
| Brain Penetration Technology | 85 |
| Biotechnology Sector Trends | 70 |
| Market Competition | 65 |
| Factor | Score |
|---|---|
| Valuation | 40 |
| Profitability | 10 |
| Growth | 0 |
| Balance Sheet Health | 40 |
| Cash Flow | 15 |
| Debt Level | 60 |
| Factor | Score |
|---|---|
| Trend Analysis | 40 |
| Momentum | 70 |
| Volume Confirmation | 60 |
| Support & Resistance | 50 |
| Price Performance | 30 |
AI Investing Checklist
Powered by LiveAIBullish Points (8)
Positive Short-Term Performance
The stock has shown strong short-term performance, with a 1-month return of 26.38% and a year-to-date (YTD) return of 38.79%.
Consistent EPS Beats
Black Diamond Therapeutics (BDTX) has consistently beaten earnings per share (EPS) estimates, notably in Q2 2025 (estimate 0.02 vs. reported 0.98, surprise 4511.76%) and Q1 2025 (estimate -0.31 vs. reported -0.28, surprise 11.03%).
Bearish Points (9)
Significant Price Drop and High Beta
The stock price has decreased by 4.81% during the trading day and experienced a 1-year price change of -50.66%. The Beta (1Y) of 2.72 suggests high volatility and a greater sensitivity to market movements.
High P/E Ratio with Negative Earnings
The Price-to-Earnings (P/E) ratio on a trailing twelve months (TTM) basis is 49.5, while the company has reported negative net income in recent annual periods (e.g., -$69.68M in 2024), indicating a high valuation relative to current profitability, which is common for clinical-stage biotech firms but carries inherent risk.
Calendar
August 2025
7
Next Earnings Date
H: $-0.21
A: $-0.23
L: $-0.24
Profile
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Seasonals
Price Target
10.67 USD
The 39 analysts offering 1 year price forecasts for BDTX have a max estimate of 12.00 and a min estimate of 9.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor specializing in RAS pathway inhibitors, a key area of focus for precision oncology and Black Diamond's pipeline.
Weight: 92
Focuses on conformational drug design to address challenging cancer targets, similar to Black Diamond's allosteric approach in precision oncology.
Weight: 88
Clinical-stage biotechnology company developing precision medicines for cancer, including small molecule inhibitors.
Weight: 87
Utilizes synthetic lethality to discover and develop precision oncology drugs, a complementary approach within targeted cancer therapies.